AFC
SYRE icon

Ares Financial Consulting’s Spyre Therapeutics SYRE Stock Holding History

Ares Financial Consulting’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977 Buy
+11
New +$803 ﹤0.01% 1012

Other funds holding SYRE

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Ares Financial Consulting's SYRE Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 11 shares worth $977. The stake represents ﹤0.01% of the portfolio and ranks #1012 among its holdings.

8 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Ares Financial Consulting held 11 shares of Spyre Therapeutics worth $977 as of Q2 2026.
  • Spyre Therapeutics was a new Ares Financial Consulting position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1012 holding.
  • 8 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.